10:42 AM EDT, 06/17/2025 (MT Newswires) -- Ventyx Biosciences ( VTYX ) shares were down 17% in recent trading Tuesday after topline data from its phase 2a study of its drug candidate VTX3232 in patients with early-stage Parkinson's disease showed Tier 2 exploratory brain-related biomarkers remained unchanged or fluctuated within normal levels.

The study achieved its primary safety and tolerability objective, with no drug-related adverse events and confirmed high drug exposure in plasma and cerebrospinal fluid, the company said.

The results met the company's internal criteria for further development of the drug for Parkinson's disease patients, with plans for a dose-ranging phase 2 study underway.

Ventyx said top-line results for the 12-week study of VTX3232 in patients with obesity and cardiometabolic risk factors are expected in H2.

Price: 2.15, Change: -0.39, Percent Change: -15.35